Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
Status:
Not yet recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
The investigators will recruit 30 children and adolescents (15 per group x 2 groups) aged 6
to 17 years with ASD and significant repetitive behaviors that cause problems to them and to
others around them. Subjects will be randomized to either amitriptyline (AMI), dosed flexibly
according to response and tolerability with a maximum dose of 100mg per day or 1.5mg/kg/day,
in divided doses to minimize side effects, or placebo in look-alike capsules, for 12 weeks.
Rating scales, and eye-tracking will be used to measure outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
University of Missouri, Kansas City
Treatments:
Amitriptyline Amitriptyline, perphenazine drug combination